NO20001238L - Monoklonalt antistoff som induserer apoptose - Google Patents

Monoklonalt antistoff som induserer apoptose

Info

Publication number
NO20001238L
NO20001238L NO20001238A NO20001238A NO20001238L NO 20001238 L NO20001238 L NO 20001238L NO 20001238 A NO20001238 A NO 20001238A NO 20001238 A NO20001238 A NO 20001238A NO 20001238 L NO20001238 L NO 20001238L
Authority
NO
Norway
Prior art keywords
antibody
monoclonal antibody
associated proteins
human integrin
apoptosis
Prior art date
Application number
NO20001238A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001238D0 (no
Inventor
Naoshi Fukushima
Shinsuke Uno
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20001238D0 publication Critical patent/NO20001238D0/no
Publication of NO20001238L publication Critical patent/NO20001238L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20001238A 1997-09-11 2000-03-09 Monoklonalt antistoff som induserer apoptose NO20001238L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26485397 1997-09-11
PCT/JP1998/004118 WO1999012973A1 (fr) 1997-09-11 1998-09-11 Anticorps monoclonal induisant l'apoptose

Publications (2)

Publication Number Publication Date
NO20001238D0 NO20001238D0 (no) 2000-03-09
NO20001238L true NO20001238L (no) 2000-05-11

Family

ID=17409137

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001238A NO20001238L (no) 1997-09-11 2000-03-09 Monoklonalt antistoff som induserer apoptose

Country Status (14)

Country Link
US (1) US20030157100A1 (fr)
EP (1) EP1035132B1 (fr)
KR (2) KR20010023866A (fr)
CN (1) CN1198845C (fr)
AT (1) ATE395362T1 (fr)
AU (1) AU740225B2 (fr)
CA (1) CA2303072A1 (fr)
DE (1) DE69839492D1 (fr)
HU (1) HUP0003513A3 (fr)
NO (1) NO20001238L (fr)
PL (1) PL339265A1 (fr)
RU (1) RU2212413C2 (fr)
SK (1) SK3232000A3 (fr)
WO (1) WO1999012973A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI960567L (fi) * 1993-09-03 1996-02-07 Chugai Pharmaceutical Co Ltd Monoklonaalinen vasta-aine, joka indusoi apoptoosin
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
EP1167388A4 (fr) * 1999-03-10 2002-05-29 Chugai Pharmaceutical Co Ltd Fv monocatenaire induisant l'apoptose
TWI241345B (en) * 2000-03-10 2005-10-11 Chugai Pharmaceutical Co Ltd Apoptosis inducing polypeptide
US20040058393A1 (en) * 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
WO2001079494A1 (fr) * 2000-04-17 2001-10-25 Chugai Seiyaku Kabushiki Kaisha Anticorps agonistes
RU2430927C2 (ru) * 2000-10-20 2011-10-10 Тугаи Сейяку Кабусики Кайся Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу
WO2002033072A1 (fr) * 2000-10-20 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Anticorps degrade, agoniste de tpo
US8034903B2 (en) 2000-10-20 2011-10-11 Chugai Seiyaku Kabushiki Kaisha Degraded TPO agonist antibody
US20040242847A1 (en) * 2000-10-20 2004-12-02 Naoshi Fukushima Degraded agonist antibody
EP1327681A4 (fr) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Anticorps agoniste degrade
EP2075256A2 (fr) 2002-01-14 2009-07-01 William Herman Ligands ciblés
AU2003271175A1 (en) 2002-10-11 2004-05-04 Masahiro Abe Cell death-inducing agent
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
WO2004087763A1 (fr) * 2003-03-31 2004-10-14 Chugai Seiyaku Kabushiki Kaisha Anticorps modifie dirige contre cd22 et son utilisation
US8613922B2 (en) * 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US8101719B2 (en) 2003-11-11 2012-01-24 Chugai Seiyaku Kabushiki Kaisha Humanized anti-CD47 antibody
JPWO2005056602A1 (ja) * 2003-12-12 2008-03-06 中外製薬株式会社 アゴニスト活性を有する改変抗体のスクリーニング方法
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
KR20060130606A (ko) * 2003-12-12 2006-12-19 추가이 세이야쿠 가부시키가이샤 세포사 유도제
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
EP1870458B1 (fr) 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha ISOMERES STRUCTURELS sc(Fv)2
WO2006123724A1 (fr) * 2005-05-18 2006-11-23 The University Of Tokushima Nouvel agent pharmaceutique a base d’un anticorps anti-hla
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
CA2610987C (fr) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilisant pour une preparation de proteine contenant de la meglumine et son utilisation
US20070113297A1 (en) * 2005-09-13 2007-05-17 Yongguang Yang Methods and compositions for inhibition of immune responses
MX2009000487A (es) * 2006-07-13 2009-01-27 Chugai Pharmaceutical Co Ltd Inductor de muerte celular.
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
PL4160212T3 (pl) 2008-01-15 2024-08-12 The Board Of Trustees Of The Leland Stanford Junior University Markery komórek macierzystych ostrej białaczki szpikowej
FI3056514T4 (fi) 2008-01-15 2025-10-06 Univ Leland Stanford Junior Menetelmät cd47:n välittämän fagosytoosin manipuloimiseksi
AU2009279676C1 (en) 2008-08-07 2015-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radioprotectants targeting thrombospondin-1 and CD47
KR102338833B1 (ko) * 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
HK1216647A1 (zh) 2012-12-12 2016-11-25 Vasculox Inc. 治疗性cd47抗体
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
EP3349787A4 (fr) 2015-09-18 2019-03-27 Arch Oncology, Inc. Anticorps cd47 thérapeutiques
JP2019522486A (ja) 2016-07-13 2019-08-15 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗原提示細胞模倣足場およびそれを作製および使用するための方法
WO2018075960A1 (fr) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Anticorps cd47 thérapeutiques
KR20200091901A (ko) 2017-12-01 2020-07-31 시애틀 지네틱스, 인크. 암을 치료하기 위한 cd47 항체 및 이의 용도
CN110066336B (zh) * 2019-05-12 2021-11-09 杭州科兴生物科技有限公司 抗cd47单克隆抗体、片段及其医药用途
CN118829725A (zh) 2021-10-28 2024-10-22 莱尔免疫制药公司 生成细胞的方法
WO2024077174A1 (fr) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Procédés de culture de cellules déficientes en nr4a
WO2025217398A1 (fr) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Procédés de culture de cellules avec milieu de culture amélioré
WO2026006604A1 (fr) 2024-06-26 2026-01-02 Lyell Immunopharma, Inc. Substitution de cellules nourricières

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0672142T3 (da) * 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
FI960567L (fi) * 1993-09-03 1996-02-07 Chugai Pharmaceutical Co Ltd Monoklonaalinen vasta-aine, joka indusoi apoptoosin
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
EP0903149A4 (fr) * 1996-03-06 2002-02-13 Chugai Pharmaceutical Co Ltd Procede de criblage de substances induisant l'apoptose
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7696325B2 (en) * 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis

Also Published As

Publication number Publication date
EP1035132B1 (fr) 2008-05-14
AU740225B2 (en) 2001-11-01
SK3232000A3 (en) 2000-09-12
NO20001238D0 (no) 2000-03-09
KR20010023866A (ko) 2001-03-26
HUP0003513A3 (en) 2004-05-28
ATE395362T1 (de) 2008-05-15
DE69839492D1 (de) 2008-06-26
EP1035132A1 (fr) 2000-09-13
CN1198845C (zh) 2005-04-27
RU2212413C2 (ru) 2003-09-20
KR20040106585A (ko) 2004-12-17
US20030157100A1 (en) 2003-08-21
HUP0003513A2 (hu) 2001-02-28
CA2303072A1 (fr) 1999-03-18
CN1276798A (zh) 2000-12-13
WO1999012973A1 (fr) 1999-03-18
EP1035132A4 (fr) 2005-02-09
AU9002898A (en) 1999-03-29
PL339265A1 (en) 2000-12-04

Similar Documents

Publication Publication Date Title
NO20001238L (no) Monoklonalt antistoff som induserer apoptose
FI960567A0 (fi) Monoklonaalinen vasta-aine, joka indusoi apoptoosin
MX9603080A (es) Anticuerpos monoclonales inmuno-estimulantes.
EP1565489A4 (fr) Cible de surface cellulaire raag10 et famille d'anticorps reconnaissant cette cible
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
DE68923027D1 (de) Antigene.
PT921395E (pt) Ensaio para medicao de fragmentos de proteina em meios biologicos
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
ES2133738T3 (es) Metodo para cuantificar lbp en fluidos corporales.
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
MX9706588A (es) Metodo para estimular una respuesta inmune.
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
DE69504959D1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
CY1106349T1 (el) Συστηματα ανιχνευσης ανοσοπροσδιορισμου ιικου αντιγονου ηπατιτιδας c
BR9903250A (pt) Antìgenos e imunoanálises para diagnóstico da doença de chagas.
PT744027E (pt) Utilizacao de metodos para identificar oligopeptidos de sinal hidrofilicos
ATE160359T1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
EP0585364A4 (fr) Ctaa 81av78, l'antigene reconnu par l'anticorps monoclonal humain 81av78.
ES2099678B1 (es) Procedimiento para la inactivacion de virus en proteinas.
DE69132144D1 (de) Menschliche phospholipase aktivierender proteinteil
KR100310413B1 (ko) 인간의자연형lgM항체
DE69533904D1 (de) Chemische Modifikation von Antikörpern und Antigenen
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
DK34393D0 (da) Humant foetalt antigen 1 (fa1), anvendelse af fa1 og anti-fa1 specifikke antistoffer som biologiske principper og immunoreagenser samt kvantitive teknikker baseret herpaa